Acalovschi M, Blendea D, Feier C, Letia AI, Ratiu N, Dumitrascu DL, etal. (August 2003). "Risk factors for symptomatic gallstones in patients with liver cirrhosis: a case-control study". The American Journal of Gastroenterology. 98 (8): 1856–1860. doi:10.1111/j.1572-0241.2003.07618.x. ISSN0002-9270.
Koppisetti S, Jenigiri B, Terron MP, Tengattini S, Tamura H, Flores LJ, etal. (October 2008). "Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review". Digestive Diseases and Sciences. 53 (10): 2592–603. doi:10.1007/s10620-007-0195-5. PMID18338264. S2CID22785223.
Kan HP, Guo WB, Tan YF, Zhou J, Liu CD, Huang YQ (September 2015). "Statin use and risk of gallstone disease: A meta-analysis". Hepatology Research. 45 (9): 942–948. doi:10.1111/hepr.12433. PMID25297889. S2CID25636425.
Paumgartner G, Sauter GH (May 2005). "Extracorporeal shock wave lithotripsy of gallstones: 20th anniversary of the first treatment". European Journal of Gastroenterology & Hepatology. 17 (5): 525–527. doi:10.1097/00042737-200505000-00009. PMID15827443.
Thistle JL, Hofmann AF (September 1973). "Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones". The New England Journal of Medicine. 289 (13): 655–9. doi:10.1056/NEJM197309272891303. PMID4580472.
Hofmann AF (September 1989). "Medical dissolution of gallstones by oral bile acid therapy". American Journal of Surgery. 158 (3): 198–204. doi:10.1016/0002-9610(89)90252-3. PMID2672842.
Koppisetti S, Jenigiri B, Terron MP, Tengattini S, Tamura H, Flores LJ, etal. (October 2008). "Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review". Digestive Diseases and Sciences. 53 (10): 2592–603. doi:10.1007/s10620-007-0195-5. PMID18338264. S2CID22785223.
Kan HP, Guo WB, Tan YF, Zhou J, Liu CD, Huang YQ (September 2015). "Statin use and risk of gallstone disease: A meta-analysis". Hepatology Research. 45 (9): 942–948. doi:10.1111/hepr.12433. PMID25297889. S2CID25636425.
Paumgartner G, Sauter GH (May 2005). "Extracorporeal shock wave lithotripsy of gallstones: 20th anniversary of the first treatment". European Journal of Gastroenterology & Hepatology. 17 (5): 525–527. doi:10.1097/00042737-200505000-00009. PMID15827443.
Zackria R, Lopez RA (January 2019). "Postcholecystectomy Syndrome". StatPearls. PMID30969724.
Thistle JL, Hofmann AF (September 1973). "Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones". The New England Journal of Medicine. 289 (13): 655–9. doi:10.1056/NEJM197309272891303. PMID4580472.
Hofmann AF (September 1989). "Medical dissolution of gallstones by oral bile acid therapy". American Journal of Surgery. 158 (3): 198–204. doi:10.1016/0002-9610(89)90252-3. PMID2672842.
Koppisetti S, Jenigiri B, Terron MP, Tengattini S, Tamura H, Flores LJ, etal. (October 2008). "Reactive oxygen species and the hypomotility of the gall bladder as targets for the treatment of gallstones with melatonin: a review". Digestive Diseases and Sciences. 53 (10): 2592–603. doi:10.1007/s10620-007-0195-5. PMID18338264. S2CID22785223.
Kan HP, Guo WB, Tan YF, Zhou J, Liu CD, Huang YQ (September 2015). "Statin use and risk of gallstone disease: A meta-analysis". Hepatology Research. 45 (9): 942–948. doi:10.1111/hepr.12433. PMID25297889. S2CID25636425.
Acalovschi M, Blendea D, Feier C, Letia AI, Ratiu N, Dumitrascu DL, etal. (August 2003). "Risk factors for symptomatic gallstones in patients with liver cirrhosis: a case-control study". The American Journal of Gastroenterology. 98 (8): 1856–1860. doi:10.1111/j.1572-0241.2003.07618.x. ISSN0002-9270.